Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

David Kaminetzky1, Kenneth B Hymes21Division of Hematology/Oncology, New York University School of Medicine, New York, USA; 2New York University Cancer Institute, New York, USAAbstract: Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David Kaminetzky, Kenneth B Hymes
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/7f82a9298b1741aeb1c6a723b6e91f15
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7f82a9298b1741aeb1c6a723b6e91f15
record_format	dspace
spelling	oai:doaj.org-article:7f82a9298b1741aeb1c6a723b6e91f152021-12-02T02:49:25ZDenileukin diftitox for the treatment of cutaneous T-cell lymphoma1177-54751177-5491https://doaj.org/article/7f82a9298b1741aeb1c6a723b6e91f152008-12-01T00:00:00Zhttp://www.dovepress.com/denileukin-diftitox-for-the-treatment-of-cutaneous-t-cell-lymphoma-a2673https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491David Kaminetzky1, Kenneth B Hymes21Division of Hematology/Oncology, New York University School of Medicine, New York, USA; 2New York University Cancer Institute, New York, USAAbstract: Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is progression despite application of these treatments, or if the patient presents with a higher stage of disease, systemic chemotherapy or retinoids, rexinoids, biologic response modifiers are often necessary. Consequently, patients are often treated with a sequence of modalities and drugs. Denileukin diftitox (DD, Ontak&reg;) is a targeted immunotoxin which has biological activity against malignancies expressing the IL-2 receptor. In addition to its unique mechanism of action, DD has a toxicity profile which does not overlap with most commonly used chemotherapeutic agents. CTCL/MF has been found be particularly susceptible to treatment with this agent. This review will describe the development DD, its proposed mechanism of action, the clinical trials which identified its utility in the treatment of CTCL/MF, the common toxicities encountered with this agent, and the management of these toxicities. In addition the incorporation of DD in the sequential treatment of CTCL/MF and data suggesting potential combination therapies employing this novel agent will be discussed.Keywords: T-cell lymphoma, mycosis fungoides, immunotoxin, cytokine therapy, denileukin diftitiox David KaminetzkyKenneth B HymesDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 717-724 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 David Kaminetzky Kenneth B Hymes Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
description	David Kaminetzky1, Kenneth B Hymes21Division of Hematology/Oncology, New York University School of Medicine, New York, USA; 2New York University Cancer Institute, New York, USAAbstract: Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is progression despite application of these treatments, or if the patient presents with a higher stage of disease, systemic chemotherapy or retinoids, rexinoids, biologic response modifiers are often necessary. Consequently, patients are often treated with a sequence of modalities and drugs. Denileukin diftitox (DD, Ontak&reg;) is a targeted immunotoxin which has biological activity against malignancies expressing the IL-2 receptor. In addition to its unique mechanism of action, DD has a toxicity profile which does not overlap with most commonly used chemotherapeutic agents. CTCL/MF has been found be particularly susceptible to treatment with this agent. This review will describe the development DD, its proposed mechanism of action, the clinical trials which identified its utility in the treatment of CTCL/MF, the common toxicities encountered with this agent, and the management of these toxicities. In addition the incorporation of DD in the sequential treatment of CTCL/MF and data suggesting potential combination therapies employing this novel agent will be discussed.Keywords: T-cell lymphoma, mycosis fungoides, immunotoxin, cytokine therapy, denileukin diftitiox
format	article
author	David Kaminetzky Kenneth B Hymes
author_facet	David Kaminetzky Kenneth B Hymes
author_sort	David Kaminetzky
title	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
title_short	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
title_full	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
title_fullStr	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
title_full_unstemmed	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
title_sort	denileukin diftitox for the treatment of cutaneous t-cell lymphoma
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/7f82a9298b1741aeb1c6a723b6e91f15
work_keys_str_mv	AT davidkaminetzky denileukindiftitoxforthetreatmentofcutaneoustcelllymphoma AT kennethbhymes denileukindiftitoxforthetreatmentofcutaneoustcelllymphoma
_version_	1718402109505798144

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

Ejemplares similares